Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2‐negative metastatic breast cancer: A real‐world multicenter study

Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2‐negative metastatic breast cancer: A real‐world multicenter study

Abstract Background Chidamide is a selective histone deacetylase inhibitor approved for patients with hormone receptor (HoR)‐positive and HER2‐negative metastatic breast cancer (MBC). We aimed to investigate the efficacy, safety, and treatment patterns of chidamide and identify clinicopathological f...

Full description

Bibliographic Details
Main Authors: Doudou Li, Yizi Jin, Mingxi Lin, Cheng Zeng, Qing Guo, Yanfei Liu, Jian Zhang
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Medicine
Subjects:
chidamide
endocrine therapy
hormone receptor‐positive
metastatic breast cancer
real‐world data
Online Access:https://doi.org/10.1002/cam4.6762

Internet

https://doi.org/10.1002/cam4.6762

Similar Items